(RTTNews) - Evaxion Biotech (EVAX), a clinical-stage TechBio company, announced on Wednesday that it has completed dosing for all 16 patients in its Phase 2 trial of EVX-01, a personalized cancer vaccine designed for advanced melanoma.
EVX-01, developed using Evaxion's AI-Immunology platform, is being tested in combination with Merck's KEYTRUDA or pembrolizumab in patients with advanced melanoma. The trial remains on schedule, with the final data readout expected in the second half of 2025.
Interim data presented at the European Society for Medical Oncology or ESMO Congress in September 2024 showed promising results, including a 69 percent overall response rate and tumor reductions in 15 of 16 patients.
Additionally, the data revealed a strong correlation between immune responses and AI-Immunology platform predictions, further supporting the potential of EVX-01 as a personalized treatment.
EVX-01 is designed to engage the patient's immune system by targeting each individual's unique tumor profile.
The Phase 2 trial's success underscores Evaxion's commitment to advancing personalized immunotherapies, and the company is optimistic about the vaccine's potential for treating advanced melanoma.
Evaxion's CEO, Christian Kanstrup, expressed confidence in the trial's progress, highlighting the growing commercial potential of EVX-01 in addressing the significant medical needs of melanoma patients. Currently, EVAX is trading at $3.45 down 5.73%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
